For resectable NSCLC, atezolizumab was recently approved as adjuvant treatment after platinum-based CT for patients expressing PD-L1 ≥ 1% [41], and nivolumab plus platinum-based CT was also approved as neoadjuvant treatment [32]. Here, CD274 is linked to non-small cell lung carcinoma.